First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: A systematic review of published randomized controlled trials

Anti-Cancer Drugs

Volumn 27, Issue 5, 2016, Pages 383-397

  Takyar, Shweta ^a   Diaz, Jose ^b   Sehgal, Manu ^a   Sapunar, Francisco ^c   Pandha, Hardev ^d  

^a PAREXEL INTERNATIONAL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Advanced renal cell carcinoma; First line treatment; Metastatic renal cell carcinoma; Systematic review; Treatment naive patients

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CEDIRANIB; NINTEDANIB; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; RAPAMYCIN; SULFONAMIDE;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EPISTAXIS; FATIGUE; FEVER; FLANK PAIN; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INFECTION; INFESTATION; KIDNEY METASTASIS; LEUKOPENIA; LYMPHOCYTOPENIA; MENTAL DISEASE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VASCULAR DISEASE; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; METASTASIS; PATHOLOGY; PSYCHOLOGY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARCINOMA, RENAL CELL; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIMIDINES; PYRROLES; QUALITY OF LIFE; QUINAZOLINES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; SULFONAMIDES;

EID: 84958794108     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000335     Document Type: Review

References (37)

1. IARC, WHO. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012. Available at: http://globocan. iarc.fr/Pages/fact-sheets-population.aspx. [Accessed 5 February 2015].
2. Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D, et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin 2015;65:457-480.
3. National Comprehensive Cancer Network. 2014. Available at: http://www.nccn.org/professionals/physician-gls/pdf/kidney.pdf.
4. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Available at: http://seer.cancer.gov [Accessed 5 February 2015].
5. Oudard S, George D, Medioni J, Motzer R. Treatment options in renal cell carcinoma: past, present and future. Ann Oncol 2007;18(Suppl 10):x25-x31.
6. Buti S, Bersanelli M, Sikokis A, Maines F, Facchinetti F, Bria E, et al. Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs 2013;24:535-554.
7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-3590.
8. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-2111.
9. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-5428.
10. Van Cruijsen H, Van der Veldt AA, Hoekman K. Tyrosine kinase inhibitors of VEGF receptors: clinical issues and unanswered questions. Front Biosci 2008;1:2248-2268.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
12. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-1759.
13. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010;102:803-809.
14. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913-924.
15. Eisen T, Shparyk Y, Jones R, MacLeod NJ, Temple G, Finnigan H, et al. Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients [Abstract]. J Clin Oncol 2013;31:4506.
16. Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013;31:3791-3799.
17. Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer 2012;48:527-537.
18. Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49:1287-1296.
19. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-1068.
20. Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014;32:1412-1418.
21. Negrier S, Jäger E, Porta C, McDermott D, Moore M, Bellmunt J, et al. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol 2010;27:899-906.
22. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281.
23. Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renalcell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013;14:1287-1294.
24. Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur Urol 2015;68:837-847.
25. Tomita Y, Naito S, Sassa N, Takahashi A, Kondo T, Koie T, et al. Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favorable or intermediate MSKCC risk factors: a multicenter randomized trial, CROSS-J-RCC [Abstract]. J Clin Oncol 2014;32:502.
26. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-731.
27. Negrier S, Gravis G, Perol D, Chevreau C, Delva R, Bay JO, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. T. Lancet Oncol 2011;12:673-680.
28. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280-1289.
29. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-3318.
30. Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014;370:1769-1770.
31. Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 2008;26:3763-3769.
32. de Souza P, Maart K, Laurell A, Hawkins RE, Berkenblit A, Galand L, et al. Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon[alpha] or the combination of temsirolimus + interferon[alpha]. Eur J Cancer 2007;5:282-283.
33. Yang S, de Souza P, Alemao E, Purvis J. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer 2010;102:1456-1460.
34. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011;108:1556-1563.
35. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011;16(Suppl 2):14-22.
36. Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007;99:428-432.
37. Tykodi SS. PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther 2014;7:1349-1359.